PARSIPPANY, N.J.— GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores. Glaxo's innovation center for consumer products, in Parsippany, New Jersey, says the product package was redesigned to make tampering easier to spot. Before shipping alli, known chemically as orlistat, to retail stores, Glaxo launched it in mid-February through Drugstore.com and...» Read More
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.
The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.
Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.
Incyte CEO Herve Hoppenot, provides insight to his company's progress on cancer research at this year's ASCO conference.
Ariad Pharmaceuticals CEO Dr. Harvey Berger, says investors are responding to his company's better overall picture, and the progress on its leukemia drug Iclusig.
In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.
Costco reported third-quarter results below analysts' estimates hurt by an increase in merchandise costs and other expenses.
CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.
CNBC's Meg Tirrell reports on the high cost of drug prices. Ezekial Emanuel, University of Pennsylvania; and Alex Brill, American Enterprise Institute, share their concerns and solutions for the issue.
PTC Therapeutics skyrockets on a recommendation for approval in Europe for its Duchenne Muscular Dystrophy drug. CNBC's Meg Tirrell provides insight to the disease and treatment options. Shane Kovacs, PTC Therapeutics CFO, looks at the move in the stock.
CNBC's Meg Tirrell reports why drugs in the U.S. versus the rest of the world are priced differently.
Lawmakers in four states are considering changing the rules to allow terminally ill people access to experimental drugs before they have FDA approval. Kenneth Goodman, University of Miami, thinks this would be a bad bet for patients. Miles Nadal, MDC Partners Chairman & CEO, weighs in.
CNBC's Meg Tirrell spoke with Merck Chairman & CEO Ken Frazier about the company's decision to sell its over the counter health care products to Bayer.
Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.
Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.
GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.
GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.
Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.
Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.